

Table S1. Reported cases of hepatitis E after administration of RTX:.

	underlying disease	time from last RTX administration to HEV diagnosis	immunosuppressive medication	HEV treatment	treatment outcome	n
von Felden et al. 2019 [9]	n/d	n/d	RTX/bendamustine or R-CHOP	n/d	n/d	11
Bauer et al. 2015 [12]	rheumatoid arthritis	n/d	RTX/leflunomide/MTX	discontinuation of leflunomide/MTX	n/d	4
	rheumatoid arthritis		RTX/MTX	3 months of RBV	HEV clearance	
	rheumatoid arthritis		RTX/leflunomide/steroids	discontinuation of leflunomide	n/d	
	rheumatoid arthritis		RTX/MTX	MTX replaced by leflunomide	n/d	
Fraticeilli et al. 2016 [13]	sjögren's syndrome	9 months	RTX/MMF	discontinuation of RTX/MMF 3 months of RBV 2x400 mg/d	relapse	1
Gauss et al. 2012 [14]	B-cell lymphocytic leukemia	6.5 months	RTX/pentostatin/cyclophosphamide	discontinuation of RTX	HEV clearance	1
Alnuaimie et al. 2018 [15]	indolent lymphoma	12 months	RTX/bendamustine	2 cycles of RBV	death	2
	indolent lymphoma	7 months	RTX/bendamustine	4 months of RBV (10mg/kg/d)	relapse	
Verhoeven et al. 2016 [16]	rheumatoid arthritis	7 months	RTX	2 months of RBV 2x800mg/d	HEV clearance	1
Ollier et al. 2009 [17]	non-Hodgkin lymphoma	n/d	RTX/chlorambucil/fludarabine	3 months interferon	HEV persistence	1

Abbreviations: R-CHOP – rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; MTX - methotrexate; n/d – not determined; MMF - mycophenolate mofetil